Galapagos creates new subscription right plans

Core Points - Galapagos NV has created 1,614,000 subscription rights under new plans for its personnel and subsidiaries [1] - The subscription rights have an exercise term of eight years and an exercise price of €26.90 [2] - The company currently has a total share capital of €356,444,938.61 and 65,897,071 voting rights [3] Subscription Rights Plans - Three subscription right plans have been approved: "Subscription Right Plan 2024 BE" for Belgian personnel, "Subscription Right Plan 2024 RMV" for French subsidiary employees, and "Subscription Right Plan 2024 ROW" for other non-Belgian subsidiaries [1] - The rights under the Belgian plan cannot be exercised before January 1, 2028, while the rights under the other two plans vest in installments starting from January 1, 2026 [2] Financial Overview - The total number of rights to subscribe to not yet issued securities is 11,376,759, excluding the newly created subscription rights [3] - Galapagos does not have any outstanding convertible bonds or shares without voting rights [3] Company Profile - Galapagos is a biotechnology company focused on developing transformational medicines, particularly in oncology and immunology [4] - The company emphasizes a deep pipeline of small molecules, CAR-T therapies, and biologics to address high unmet medical needs [4]